Skip to main content
×
Home
    • Aa
    • Aa
  • Access
  • Cited by 1
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Gnant, Michael Piccart-Gebhart, Martine Goldhirsch, Aron Baselga, Jose Cameron, David Di Leo, Angelo Dowsett, Mitchell Gelber, Richard von Minckwitz, Gunter Waldvogel, Cecilia and Straehle, Carolyn 2011. Developing an international network for breast cancer research: the BIG experience. Clinical Investigation, Vol. 1, Issue. 5, p. 623.


    ×

Bisphosphonates and prevention of metastases: the AZURE study

  • R. Burkinshaw (a1), H. Thorpe (a2) and R. Coleman (a1)
  • DOI: http://dx.doi.org/10.1017/S1470903107005147
  • Published online: 01 November 2007
Abstract
Abstract

Most patients present with disease that appears to be confined to the breast. However, a significant proportion of women will go on to develop metastatic breast cancer with bone being the most frequent site of distant relapse. The bone microenvironment provides a fertile soil for circulating metastatic cells as resorbing bone releases growth factors that are thought to attract circulating cancer cells to the bone surface and facilitate their growth and proliferation. These infiltrating tumour cells in turn produce bone cell-activating factors, which lead to increased bone resorption and further release of growth factors in a ‘vicious cycle’. The third-generation bisphosphonate zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption. It also has effects on numerous processes in the metastatic cascade, with in vitro and animal studies showing synergistic antitumour effects with a range of cytotoxic and endocrine treatments. The addition of zoledronic acid to adjuvant therapy could therefore be a therapeutic strategy of potential importance.

To investigate this, the AZURE trial was designed to determine whether adjuvant zoledronic acid improves the disease-free and bone metastasis-free survival of women with stage II/III breast cancer. Recruitment of 3300 subjects was completed in January 2006. First efficacy data are expected in 2008. There is a potential for synergistic action with chemotherapy to manifest as enhanced toxicity. Reassuringly, initial safety data show that zoledronic acid is well tolerated and can be safely combined with adjuvant chemotherapy without any increase in myelotoxicity or effect on dose intensity.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Bisphosphonates and prevention of metastases: the AZURE study
      Your Kindle email address
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Bisphosphonates and prevention of metastases: the AZURE study
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Bisphosphonates and prevention of metastases: the AZURE study
      Available formats
      ×
Copyright
Corresponding author
Correspondence to: Roger Burkinshaw, Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. E-mail: r.burkinshaw@sheffield.ac.uk; Tel: +114 226 5208; Fax: +114 226 5678
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.RE Coleman . Skeletal complications of malignancy. Cancer 1997; 80: 15881594.

2.RE Coleman . Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s6249s.

3.RE Coleman . Bisphosphonates: clinical experience. Oncologist 2004; 9 (Suppl 4): 1427.

4.T Yoneda . Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000; 5: 7581.

5.JJ Yin , CB Pollock , K Kelly . Mechanisms of cancer metastasis to the bone. Cell Res 2005; 15: 5762.

6.RJ Thomas , TA Guise , JJ Yin , . Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 44514458.

7.GR Mundy . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584593.

8.GN Hortobagyi , RL Theriault , L Porter , . Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 17851791.

9.RE Coleman . Bisphosphonates in breast cancer. Ann Oncol 2005; 16: 687695.

11.LS Rosen , DH Gordon , W Dugan Jr., . Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 3643.

12.JR Green . Bisphosphonates: preclinical review. Oncologist 2004; 9 (Suppl 4): 313.

13.D Santini , U Vespasiani Gentilucci , B Vincenzi , . The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14: 14681476.

15.S Magnetto , S Boissier , PD Delmas , P Clezardin . Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83: 263269.

16.SP Jagdev , RE Coleman , CM Shipman , HA Rostami , PI Croucher . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 11261134.

17.HL Neville-Webbe , A Rostami-Hodjegan , CA Evans , RE Coleman , I Holen . Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113: 364371.

18.HL Neville Webbe , CA Evans , RE Coleman , I Holen . Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27: 92103.

20.IJ Diel , EF Solomeyer , SD Costa , . Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357363.

21.S Braun , FD Vogel , B Naume , . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793802.

23.T Powles , S Paterson , JA Kanis , . Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 32193224.

24.T Powles , A Paterson , E McCloskey , . Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer (ISRCTN83688026). Breast Cancer Res 2006; 8: R13.

26.T Saarto , L Vehmanen , P Virkkunen , C Blomqvist . Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43: 650656.

27.BE Hillner , JN Ingle , RT Chlebowski , . American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 40424057.

30.K Mystakidou , E Katsouda , E Parpa , . Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22: 195201.

31.AH Paterson . The role of bisphosphonates in early breast cancer. Oncologist 2006; 11 (Suppl 1): 1319.

32.SL Ruggiero , B Mehrotra , TJ Rosenberg , SL Engroff . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527534.

33.AI Zavras , S Zhu . Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006; 64: 917923.

35.CA Migliorati , J Casiglia , J Epstein , . Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136: 16581668.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Breast Cancer Online
  • ISSN: -
  • EISSN: 1470-9031
  • URL: /core/journals/breast-cancer-online
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: